Plain-English translation of NCT06029309 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mantle Cell Lymphoma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing whether combining two medications called and can effectively treat mantle cell lymphoma, a type of blood cancer. The study has two phases: the first phase will figure out the right dose of these medications to give together, and the second phase will see how well this combination works for patients. You would receive this treatment over about two years, with the option to continue one of the medications longer if your cancer responds well.
Mantle cell lymphoma is a serious cancer that can come back after initial treatment or may not respond to standard therapies. Researchers believe that combining these two medications might work better than using them alone, giving patients with this diagnosis a potentially more effective treatment option.
You likely qualify if…
You likely don't qualify if…
You would take both medications by mouth, with treatment divided into three induction phases over about 96 weeks (roughly 2 years), followed by maintenance therapy with one medication alone for up to 2 additional years. You would visit the study clinic regularly for blood tests, scans, and check-ins to monitor how well the treatment is working and watch for side effects. In total, your participation could last up to 4 years, though you would not need to come in as frequently during the later maintenance phase.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States